DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $210,389 | +3.4% | 848 | 0.0% | 0.02% | +4.8% |
| Q2 2023 | $203,520 | +31900.0% | 848 | -64.6% | 0.02% | -70.8% |
| Q4 2022 | $636 | -99.9% | 2,394 | 0.0% | 0.07% | -8.9% |
| Q3 2022 | $619,000 | -0.6% | 2,394 | -2.6% | 0.08% | -1.2% |
| Q2 2022 | $623,000 | +181.9% | 2,457 | +225.4% | 0.08% | +207.7% |
| Q1 2022 | $221,000 | -4.3% | 755 | +7.7% | 0.03% | +18.2% |
| Q4 2021 | $231,000 | -12.5% | 701 | -28.8% | 0.02% | -29.0% |
| Q2 2021 | $264,000 | +15.3% | 985 | -3.0% | 0.03% | +10.7% |
| Q1 2021 | $229,000 | +0.9% | 1,015 | -0.5% | 0.03% | -6.7% |
| Q4 2020 | $227,000 | +3.7% | 1,020 | 0.0% | 0.03% | -6.2% |
| Q3 2020 | $219,000 | +33.5% | 1,020 | -18.0% | 0.03% | +23.1% |
| Q1 2019 | $164,000 | +80.2% | 1,244 | +41.5% | 0.03% | +116.7% |
| Q4 2018 | $91,000 | -5.2% | 879 | 0.0% | 0.01% | -14.3% |
| Q3 2018 | $96,000 | -26.2% | 879 | -33.5% | 0.01% | -22.2% |
| Q2 2018 | $130,000 | +7.4% | 1,321 | +7.3% | 0.02% | +5.9% |
| Q1 2018 | $121,000 | +4.3% | 1,231 | -1.4% | 0.02% | 0.0% |
| Q4 2017 | $116,000 | +63.4% | 1,248 | +48.9% | 0.02% | +54.5% |
| Q3 2017 | $71,000 | -35.5% | 838 | -35.9% | 0.01% | -54.2% |
| Q2 2017 | $110,000 | -8.3% | 1,307 | -6.8% | 0.02% | -7.7% |
| Q1 2017 | $120,000 | +6.2% | 1,402 | -3.2% | 0.03% | +4.0% |
| Q4 2016 | $113,000 | -24.7% | 1,448 | -24.5% | 0.02% | -30.6% |
| Q3 2016 | $150,000 | -23.9% | 1,919 | -1.6% | 0.04% | -29.4% |
| Q2 2016 | $197,000 | +101.0% | 1,950 | +88.4% | 0.05% | +104.0% |
| Q1 2016 | $98,000 | 0.0% | 1,035 | -1.4% | 0.02% | +19.0% |
| Q4 2015 | $98,000 | -2.0% | 1,050 | -10.3% | 0.02% | -22.2% |
| Q3 2015 | $100,000 | -79.2% | 1,171 | -79.1% | 0.03% | -76.9% |
| Q2 2015 | $481,000 | +0.8% | 5,614 | 0.0% | 0.12% | +1.7% |
| Q1 2015 | $477,000 | -0.4% | 5,614 | +0.5% | 0.12% | -8.0% |
| Q4 2014 | $479,000 | +13.0% | 5,584 | 0.0% | 0.12% | -6.0% |
| Q3 2014 | $424,000 | -3.6% | 5,584 | 0.0% | 0.13% | +49.4% |
| Q2 2014 | $440,000 | +5.0% | 5,584 | 0.0% | 0.09% | +1.1% |
| Q1 2014 | $419,000 | – | 5,584 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |